For the readers interested in the stock health of Lineage Cell Therapeutics Inc. (LCTX). It is currently valued at $1.88. When the transactions were called off in the previous session, Stock hit the highs of $2.03, after setting-off with the price of $2.00. Company’s stock value dipped to $1.88 during the trading on the day. When the trading was stopped its value was $2.02.Recently in News on January 4, 2022, Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference. Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright Bioconnect Virtual Conference. The corporate presentation will be available to investors on demand, starting on January 10, 2022 at 7:00am ET on the Events and Presentations section of Lineage’s website. You can read further details here
Lineage Cell Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.58 on 01/03/22, with the lowest value was $1.88 for the same time period, recorded on 01/12/22.
Lineage Cell Therapeutics Inc. (LCTX) full year performance was -7.84%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Lineage Cell Therapeutics Inc. shares are logging -39.97% during the 52-week period from high price, and 21.29% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.55 and $3.13.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1129910 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Lineage Cell Therapeutics Inc. (LCTX) recorded performance in the market was -23.27%, having the revenues showcasing -21.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 329.66M, as it employees total of 49 workers.
Market experts do have their say about Lineage Cell Therapeutics Inc. (LCTX)
During the last month, 4 analysts gave the Lineage Cell Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.36, with a change in the price was noted -0.41. In a similar fashion, Lineage Cell Therapeutics Inc. posted a movement of -17.90% for the period of last 100 days, recording 1,033,283 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for LCTX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Lineage Cell Therapeutics Inc. (LCTX)
Raw Stochastic average of Lineage Cell Therapeutics Inc. in the period of last 50 days is set at 8.79%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 8.79%. In the last 20 days, the company’s Stochastic %K was 18.32% and its Stochastic %D was recorded 21.25%.
Bearing in mind the latest performance of Lineage Cell Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -23.27%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -30.37%, alongside a downfall of -7.84% for the period of the last 12 months. The shares increased approximately by -9.18% in the 7-day charts and went down by -5.05% in the period of the last 30 days. Common stock shares were lifted by -21.01% during last recorded quarter.